We recently compiled a list of the Jim Cramer on Nvidia Plus Other Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer was talking about.

Jim Cramer, host of Mad Money, recently observed that consumers are no longer focused on brand names but are instead prioritizing companies that offer the best value. Cramer noted that there is a noticeable shift happening in the market, saying:

“We’ve become a nation of cheapskates. I say that as a compliment. Nobody gets away with charging too much anymore, not in this country, no matter what industry, perhaps even the drug industry.”

He pointed out that this shift is happening rapidly, and many companies are being left behind as consumer behavior changes. Cramer said that he has observed this shift firsthand in various settings, including grocery stores, online, malls, and even the stock market.

READ ALSO Jim Cramer Recently Discussed These 7 Stocks and Jim Cramer’s Lightning Round: 8 Stocks to Watch

Cramer went on to explain that Americans are increasingly fed up with high prices. He said:

“The American people are tired of paying up. They feel gouged, they feel betrayed. They feel that the only thing about brand loyalty is that it isn’t worth a dime. They want a better deal. They’ll eagerly switch lifetime habits in order to save some money because prices are up so much that you feel like an idiot if you’re paying up.”

Reflecting on the market dynamics, Cramer shared his insights from Wednesday’s trading session. Cramer noted that the Dow gained 139 points, the S&P remained flat, and the Nasdaq dipped 0.11%, while the midday trading was much more challenging. He emphasized that the trend toward value is not confined to retail alone but is expanding into other sectors, including tech.

At the end, Cramer summed up the situation by saying:

“Prices have gotten so high over the past few years that we’re losing our loyalty to brands. These days, this whole country is about one thing: The Benjamins.”

Our Methodology

For this article, we compiled a list of 8 stocks that were discussed by Jim Cramer during the recent episode of Mad Money on November 20. We listed the stocks in ascending order of their hedge fund sentiment as of the third quarter, which was taken from Insider Monkey’s database of 900 hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 106

Here’s what Cramer had to say about Eli Lilly and Company (NYSE:LLY):

“You see the kind of bargain hunting I’m talking about everywhere these days, even in pharma… How could the price of one class of drugs be so important? I think it’s because there’s a scarcity of GLP-1s, even with Eli Lilly… going all out. It’s only going to get better though because Lilly’s spending billions to build more plants in order to meet the demand for the wonder drug. No one else can do that. They aren’t rich enough. The GLP-1s, they represent value because it’s not just about diabetes and weight loss, they’re lifesavers… GLP-1’s not some simple hack drug, it’s a revolution in healthcare. No wonder Eli Lilly can charge such a huge premium. It’s valuable.”

Eli Lilly (NYSE:LLY), a prominent global pharmaceutical company, is known for its broad portfolio of treatments, including insulin products for diabetes and therapies for obesity and type 2 diabetes. The company’s diabetes drug Mounjaro and its sibling medication for chronic weight management, Zepbound, have quickly become major contributors to its success.

In its most recent third-quarter earnings report, Eli Lilly saw a 20% year-over-year increase in revenue, reaching $11.4 billion. Mounjaro alone generated $3.11 billion in sales, marking a striking 121% growth compared to the same period last year. Zepbound earned nearly $1.26 billion in sales during this quarter.

In September, Eli Lilly (NYSE:LLY) committed nearly $2 billion to expand its manufacturing operations in Ireland. This brings the total investments in building, upgrading, and acquiring manufacturing facilities since 2020 to over $20 billion. In addition to this $20 billion commitment, the company also unveiled a separate $4.5 billion investment in October to create the Lilly Medicine Foundry.

This unique facility will focus on research and development for manufacturing process design and the production of high-quality investigational medicines for its clinical trials. The Lilly Medicine Foundry is set to open in late 2027 in Lebanon, Indiana.

Overall LLY ranks 2nd on our list of the stocks Jim Cramer was talking about. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article is originally published at Insider Monkey.